Small Pharma has reported positive results from its study investigating the interaction of SSRIs and SPL026 – the company’s native DMT – in patients with Major...
Cybin Inc.
In the face of escalating climate, economic and mental health crises, millions are seeking legal, safe ways to experience magic mushrooms (psilocybin) and other psychoactive plant...
A new research review has explored the use of psilocybin for the treatment of resistant depression.
Johns Hopkins University School of Medicine (JHU) and Clearmind Medicine will be collaborating on research to investigate the use of a novel psychoactive molecule to treat...
Awakn Life Sciences has submitted a clinical trial application to investigate the use of AWKN-P001 – a novel combined therapeutic of an N-methyl-D-aspartate receptor-modulating drug (ketamine)...
A new study has shown how trained human coders were able to identify observable markers of therapeutic connection during psilocybin administration in psychedelic-assisted therapy.
Cybin Inc.
atai Life Sciences has announced results from its Phase 1 Study of DMX-1002 (Ibogaine) for the treatment of opioid use disorder (OUD).
The Indigenous Medicine Conservation Fund (IMC Fund) took part in the 2023 Parliament of the World’s Religions (PoWR) held at McCormick Place Lakeside Center in Chicago,...